Annovis Bio Company Insiders
ANVS Stock | USD 6.65 0.14 2.06% |
Annovis Bio's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Annovis Bio suggests that vertually all insiders are extremely bullish. Annovis Bio employs about 6 people. The company is managed by 12 executives with a total tenure of roughly 61 years, averaging almost 5.0 years of service per executive, having 0.5 employees per reported executive.
Annovis Bio's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2021-10-11 | Maria-Luisa Maccecchini | Acquired 18000 @ 27.61 | View |
Monitoring Annovis Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Annovis |
Annovis Bio's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Annovis Bio's future performance. Based on our forecasts, it is anticipated that Annovis will maintain a workforce of slightly above 6 employees by December 2024.Annovis Bio Management Team Effectiveness
The company has return on total asset (ROA) of (1.5458) % which means that it has lost $1.5458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.967) %, meaning that it created substantial loss on money invested by shareholders. Annovis Bio's management efficiency ratios could be used to measure how well Annovis Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 7.61 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (5.23). At this time, Annovis Bio's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 53.7 M in 2024, despite the fact that Return On Tangible Assets are likely to grow to (5.23).Common Stock Shares Outstanding is likely to drop to about 7.3 M in 2024. Net Loss is likely to gain to about (12.4 M) in 2024
Annovis Bio Workforce Comparison
Annovis Bio is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 505. Annovis Bio claims roughly 6.0 in number of employees contributing just under 2% to equities under Health Care industry.
Annovis Bio Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Annovis Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Annovis Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Annovis Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2023-06-01 | 6.0 | 6 | 1 | 84,453 | 3,000 |
2023-03-01 | 7.0 | 7 | 1 | 106,460 | 52,755 |
2022-03-01 | 2.0 | 10 | 5 | 234,395 | 76,849 |
2020-03-01 | 0.5556 | 20 | 36 | 2,363,918 | 5,519,684 |
Annovis Bio Notable Stakeholders
An Annovis Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Annovis Bio often face trade-offs trying to please all of them. Annovis Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Annovis Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Maria Maccecchini | President, Chief Executive Officer, Founder, Director | Profile | |
Jeffrey McGroarty | Chief Financial Officer | Profile | |
Hilda Maibach | Senior Statistics | Profile | |
Michael Hoffman | Independent Director Chairman of the Board | Profile | |
RAC MS | Senior Operations | Profile | |
Claudine Bruck | Independent Director | Profile | |
MBA III | Chief Officer | Profile | |
Blake Jensen | Head Quality | Profile | |
Reid McCarthy | Independent Director | Profile | |
Cheng Fang | Senior Development | Profile | |
Melissa Gaines | Senior Operations | Profile | |
Mark White | Independent Director | Profile |
About Annovis Bio Management Performance
The success or failure of an entity such as Annovis Bio often depends on how effective the management is. Annovis Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Annovis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Annovis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (5.51) | (5.23) | |
Return On Capital Employed | (7.60) | (7.22) | |
Return On Assets | (5.51) | (5.23) | |
Return On Equity | 7.25 | 7.61 |
Please note, the imprecision that can be found in Annovis Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Annovis Bio. Check Annovis Bio's Beneish M Score to see the likelihood of Annovis Bio's management manipulating its earnings.
Annovis Bio Workforce Analysis
Traditionally, organizations such as Annovis Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Annovis Bio within its industry.Annovis Bio Manpower Efficiency
Return on Annovis Bio Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 9.4M | |
Net Loss Per Executive | 4.7M | |
Working Capital Per Employee | 988.2K | |
Working Capital Per Executive | 494.1K |
Additional Tools for Annovis Stock Analysis
When running Annovis Bio's price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.